MYC and liposarcoma: For example, the small‐molecule inhibitor ML264, which targets KLF5, mitigates colorectal cancer progression both in vivo and in vitro.[28] In liposarcoma, the bromodomain (BET) protein inhibitor ARV‐825 can inhibit the transcriptional regulatory loop composed of FOSL2, MYC and RUNX1—which holds regulatory dominance in liposarcoma and overcomes the resistance of liposarcoma to the clinical chemotherapeutic drug trabectedin.[29]